Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CUBT this does not answer the question. What are the specifics of the agreement? Typical response here.
And the added use of the PRV for the vaccine would compound that valuation.
Some here say that CUBT has done “nothing”. That is a ridiculous comment spoken out of pure ignorance. Last time I checked their portfolio of rare disease solutions has garnered a market valuation of $62M today. The goal has remained to submit the IND for the repurposing of Metformin (one of the most prescribed drugs in the world and FDA approved obviously) by the end of the year. They have now added another application to IMT504’s use. They added a world renowned surgeon to the brain cancer solution who will be the doctor doing the procedure. To say this company has done nothing is pure ignorance.
Are you familiar with the agreement between the two companies? You should post the specifics versus making just general comments. Why are you even here?
PRV’s can be be valued between $100-500M if my memory serves me right.
This move today would then significantly increase the value of the PRV for IMT504’s use to treat rabies by extending IMT504’s priority review designation for use in the vaccine for kidney patients.
And this is in line with their mission to treat rare disease cases. Big pharma would rather buy this solution than develop a one off vaccine for limited rare disease situations. Big pharma all about producing vaccines for millions of people…it is all about scale for them.
The part of the PR that caught my attention was:
“Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance, and it can be sold to another party.”
If I am reading this correctly if they receive the PRV for IMT504’s use in rabies they could then obtain priority review designation for IMT504’s use in the covid vaccine for patients with Kidney issues.
Seems this may be a tip off that the PRV for rabies is not far off.
Exciting stock indeed. Especially when one of your business leaders is from the NIH and the lead developer in repurposing Metformin to treat AMD. Patience will pay off here.
(1/4)
— Michael F. Chiang, MD (@NEIDirector) October 4, 2021
When @NatureOutlook has one of our @NatEyeInstitute Intramural researchers quoted in *three* articles, you can’t help but be proud.
Nice work, @Kapilbharti123! pic.twitter.com/APlWMIMtWT
LOL at some of these posts. Added a chunk at .1081.
He’s clear until the same post on the same topic. He is somehow determined to be correct on his erroneous thesis.
Added a few at .108 and .11. Just being patient on this one.
But he says he is neither a bear nor short this stock. LOL.
The Bears are working overtime today. It can only mean one thing. The upcoming run will be a KILLA
What is the point of posting this and once again stirring up things unnecessarily? My interpretation of your post was that Curative was doing something wrong. Not the case at all.
I’m looking at their filings on OTC markets right now. Looks like last one was amended June 30 Q.
He has said it was the goal to submit the IND by the end of the current year.
Still? Look at the price two years ago and let us know the ROI since then. Then compare that ROI to other stocks. Facts always trump fiction.
Hoping it won’t be at this level too much longer.
Garr and Michaels have also talked about a two year inflection point being critical in their solutions which puts us in Q1. They don’t want their progress to be elongated nor is it their strategy to do so.
Student of The Game is correct.
Glad to see you’re finally coming around. CUBT long and strong. Let’s go PP!!
The company’s IR needs to get to work and get more eyes on this ticker or get some partners behind them. Orphan drug designation AND IND clearance by the FDA. With the news they have released this should not be a $15M cap.
Come on man. Do t you know who the strong buy signal is? Dial in dude.
What amazing insight from the bear. LOL.
Added a few more shares today at .112 based on the clear buy signal’s return.
Patience will pay off with this one. Big things coming. Buy signal confirms. Michaels and Garr know exactly what they are doing.
Lots of wondering and speculation as the price goes up some. And the beat goes on. Instead of seeing it as a positive some posters here try to tie it to a negative event, dilution in this case. Trying to tie the price increase to dilutive events, with no specific evidence. Complete fear mongering. You can’t make this stuff up. Know what you own. $CUBT. Long and strong.
Added some more yesterday. No proof of purchase will be provided. Been down that road before. No mas. 3.2M shares now. Waiting patiently and enjoying the entertaining posts that amount to nothing more than whiney jibberish.
$QSAM Cancer treatment drug given IND approval by FDA yesterday. Now entering Phase 1. Trades today at $15M market cap. Average cap of bios in Phase 1 is $50M. Way undervalued after yesterday’s news. Great leadership in Doug Baum and Richard Piazza. Should be $1-2 stock soon.
Great news!!!!!
If that’s how you feel you better be ready.
I have no concern about Ginsberg and the other company. Looks like he’s a consultant. Very common.
Should call Steve the IR guy and ask. Suggest running your questions by him. He’s a good resource.
Can’t pass up some .08’s here.
Precursor to IND approval by the FDA. QSAM only has a $11M market cap right now, with IND announcement and phase 1 imminent for cancer drug CycloSam. Great entry point here imo.
Unlikely in my opinion that people on this board are selling after recently buying in lower ranges, settling for 30% gains vs higher rates of return. It they are so be it. I ain’t one of them and was buying at .09 range. Thinking it is market makers holding it back. Just my opinion of course. It seems some are intentionally holding it back versus taking profits here. When it goes it will really go once the right news is released.
Feeling good about the recent adds at .09 range. Long CUBT.
You actually have no idea what they have been doing with those licenses. They will release news when ready. In the meantime you can speculate all the negativity you want. Long and strong here.
Suggest you reach out to their IR person directly and ask the questions before beginning your speculation game.
Up 8.8% on 1.1M volume. Take it.
10 minutes before close it was .095. It closed at .0821 on 5K shares. Little matters in price until volume hits again which will only come with significant news. Would you have posted if those 5K shares had not sold?